Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center study assessing MB-207 for the treatment of previously transplanted X-linked severe combined immunodeficiency (XSCID) patients

Next Previous
X
Search
Trial Profile

A multi-center study assessing MB-207 for the treatment of previously transplanted X-linked severe combined immunodeficiency (XSCID) patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB 107 (Primary)
  • Indications Immunodeficiency disorders; X-linked genetic disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SUSTAIN
  • Sponsors Mustang Bio

    • Most Recent Events

    • 28 Mar 2022 According to Fortress Biotech media release, first patient is expected to enroll in the first quarter of 2023.
    • 24 Jan 2022 According to Fortress Biotech media release, U.S. Food and Drug Administration (FDA) has issued a hold, pending chemistry, manufacturing and controls clearance, on the Investigational New Drug (IND) application, submitted in december 2021. the IND is to initiate this study which is expected to start in the third quarter of 2022.
    • 17 May 2021 According to Fortress Biotech media release, IND is expected to file in the second quarter of 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top